EU agency backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON, April 26
LONDON, April 26 (Reuters) - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas.
The European Medicines Agency said on Friday its experts had also backed MAC1, a tissue-engineered medicine for cartilage defects from Sanofi, and Spedra, a new erectile dysfunction drug from Vivus.
Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- Wildfire rips through 150 homes in Northern California
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- Polls show Scottish opponents of independence with slight lead ahead of vote |
- Chinese envoy says North Korea's Kim Jong Un may visit Beijing: Yonhap
- 'Forced labor' rife in Malaysian electronics factories: report